Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery...
-
Robbins LLP is Investigating Allegations that Concorde International Group, Ltd. (CIGL) was the Subject of a Pump-and-Dump Promotion Scheme
-
Clip Money is pleased to announce its financial results for the fiscal year 2025. The Company reported record revenue growth in 2025, up 143% from 2024.
-
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. ...
-
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. ...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Concorde International Group, Ltd. (“Concorde” or the “Company”) (NASDAQ:...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Picard (PMI) To Contact Him Directly To Discuss Their Options If you purchased or...
-
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Picard Medical, Inc. (NYSE American: PMI) between September...
-
LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Concorde International Group...
-
LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PomDoctor Ltd., (“PomDoctor” or the "Company") (NASDAQ: POM) investors of a class action on behalf of investors that...